This study provides critical insight into genomic and transcriptomic mechanisms such as PBRM1 mutations, metabolic processes, immune subtypes (active or exhausted), and GATM expression that contribute to the response to ICIs therapy in patients with metastatic ccRCC. This evidence concerns the gene GATM and nonpapillary renal cell carcinoma.